Close

Karyopharm Therapeutics (KPTI) Presents Strong Selinexor Phase 2b Data in Certain Multiple Myeloma

December 5, 2016 6:12 AM EST Send to a Friend
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced updated results from its Phase 2b STORM study of selinexor (KPT-330), including robust rates ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login